The table below shows the adverse reactions that happened in 10.0% or more
of participants during the study. There were other adverse reactions, but these
happened in fewer participants.
Adverse reactions that were considered related to either
or both of the study drugs
MEDI0457 and durvalumab
Adverse reaction (out of 35 participants)
Fatigue 37.1% (13)
Reaction around the area of the body where the injection was given 25.7% (9)
Joint pain 14.3% (5)
Reaction around the area of the body where the drug was administered 11.4% (4)
Muscle aches 11.4% (4)
Rash 11.4% (4)
How has this study helped patients and
researchers?
This study helped researchers learn more about the safety of treatment with
MEDI0457 and durvalumab in people with advanced HPV-associated head and
neck cancer. It also helped them learn more about the effect of MEDI0457 and
durvalumab on tumor size.
Researchers look at the results of many studies to decide which treatments work
best and are safest. This summary shows only the main results from this one study.
Other studies may provide new information or different results.
Further clinical studies with MEDI0457 and durvalumab are not planned.
11 | Clinical Study Results